AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
COVID-19
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in...
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in...
Management Confidence: Shineco Executives Launch up to $2M Open-Market Stock Purchase Program
BEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic...
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate
Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting...
Veru to Participate in the Virtual BTIG Obesity Health Forum
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared...
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98%BERKELEY, Calif. and MAINZ, Germany,...
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall...
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual...
Nanox Receives MDR CE Mark for HealthOST, an Advanced AI-Powered Software for Spine Assessment
HealthOST identifies vertebral height loss and bone mineral density, which are key indicators of musculoskeletal diseaseOsteoporosis is a common progressive...
Mindset Medical Announces FDA Clearance for its Contactless Respiratory Rate Measurement Device
PHOENIX, June 4, 2025 /PRNewswire/ -- Mindset Medical, Inc. ("Mindset Medical" or the "Company"), a digital health company, today announced...
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented...
Manufacturing PMI® at 48.5%; May 2025 Manufacturing ISM® Report On Business®
New Orders and Backlogs Contracting; Production and Employment Contracting; Supplier Deliveries Slowing; Raw Materials Inventories Contracting; Customers' Inventories Too Low;...
Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality
This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their...
Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality
This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their...
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)...
Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to...
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless...
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...